You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News on molecular markers used to guide cancer treatment, assess prognosis, or detect relapse.
Researchers presented interim results from the pilot PEER study of Aromasin, leuprolide, and Keytruda for HR-positive, HER2-negative advanced breast cancer.
With FDA clearance of its IND, the company has begun studying the drug's dosing and preliminary activity in previously treated, ALK-positive, advanced NSCLC.
The company is testing the RAF/MEK inhibitor and FAK inhibitor combination in a randomized study after promising Phase I data presented at AACR.
The firm presented data at the AACR annual meeting that demonstrates its approach to treating HER2-positive solid cancers with engineered CAR macrophages.
The company is studying gedatolisib with palbociclib and endocrine therapy in patients with ER-positive, HER2-negative metastatic breast cancer.
The trial is evaluating Enhertu at two doses in metastatic colorectal cancer patients whose tumors overexpress HER2.
Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.
The study will evaluate the drug's activity at two different doses for patients with previously treated HER2-positive NSCLC.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
News items for the week of March 22, 2021.